Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-12-05 Major Shareholding Noti…
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2015-12-05 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2015-11-27 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes amendments to the company's bylaws and changes in quorum requirements, which are typical disclosures in an 8-K. The document is not a full annual or quarterly report, nor is it a transcript, proxy, or other specific report type. It is a regulatory filing reporting a corporate governance update. The document length is 3272 characters, which is short and consistent with an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS), as 8-Ks are general regulatory announcements that do not fit other specific categories.
2015-11-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-11-16 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-11-16 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 6, 2015, by Relmada Therapeutics, Inc. The content focuses on the departure of a director and the appointment of two new directors to the company's board, including detailed biographical information and terms of office. It also includes information about director agreements and indemnity agreements. There are no financial statements or financial performance data presented. The primary subject is changes in the company's board of directors and senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' with the code MANG. Therefore, this document should be classified as MANG with high confidence.
2015-11-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.